After Metsera Battle, Pfizer Heads to China for Another Obesity Deal Worth up to $1.9B

By /

Pfizer apparently had more in the tank after the high-profile battle to acquire Metsera earlier this fall. The company has licensed a new GLP-1 from YaoPharma.

Scroll to Top